This report provides an update on the assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing.

Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the globe.


  • Report provides in-house analyst expertise on the results of a 5 minute survey of 75 GlobalData Pharma clients and prospects, which was fielded from July 7, 2020 to July 30, 2020.

    Reasons To Buy

    Objectives included -
  • Benchmark companies’ primary concerns
  • Determine the impact of COVID-19 to date on supply chains
  • Assess companies’ strategic future plans
  • Track changes to corporate strategy and attitudes